ArticleBMJ open2026
Dose-dependent perinatal risks of clomiphene citrate in US IVF cycles: a national cohort study, 2004-2021.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe relationship between clomiphene citrate (CC) dosing regimens and adverse reproductive outcomes has not been fully elucidated, both with and without use of in vitro fertilisation (IVF). We aimed to study the association between cumulative CC dose and perinatal outcomes among fresh autologous IVF cycles.
designRetrospective cohort study.
settingWe included all fresh autologous IVF embryo transfer cycles performed in the US fertility clinics during 2004-2021 using CC for ovulation induction. We used robust Poisson regression models to estimate adjusted risk ratios (aRRs) and 95% CIs for associations between four categories of CC dose (<500 mg, 500-749 mg, 750-999 mg and ≥1000 mg) and perinatal outcomes of interest.
participants21 004 fresh autologous embryo transfer cycles using CC. PRIMARY OUTCOME MEASURES: The primary outcome measures included biochemical pregnancy, clinical pregnancy, spontaneous abortion, stillbirth, live birth, multiple birth and preterm delivery.
resultsAmong fresh autologous embryo transfer cycles using CC, 21.3% used <500 mg, 67.8% used 500-749 mg, 7.2% used 750-999 mg and 3.7% used ≥1000 mg. After adjustment, rates of spontaneous abortion were higher for patients using 500-749 mg (11.8%; aRR, 1.12; 95% CI 1.02 to 1.25) and 750-999 mg of CC (14.4%; aRR, 1.38; 95% CI 1.18 to 1.62) than for those using <500 mg (10.3%). The ≥1000 mg group had a three-fold higher rate of stillbirth than the <500 mg group, but these estimates were imprecise (0.7% vs 0.2%; aRR, 3.31; 95% CI 0.88 to 12.40). Multiple birth risk was significantly higher among all CC dosage categories compared with the <500 mg group.
conclusionOur findings extend previous findings on the association between CC exposure and adverse perinatal outcomes by demonstrating a dose-dependent relationship.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.